Objectives. To com pare the pharmacodynamics and tolerabiiity of the new goserelin acetate 10.8-mg depot with the 3.6-m g depot in patients with advanced prostate cancer during the first 3 months of therapy. Methods. One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-m g goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-m g depot every 12 weeks thereafter. Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively. Results. Serum testosterone profiles of the 10.8-mg goserelin acetate depot and the 3.6-mg goserelin ac etate depot were sim ilar; testosterone levels in both groups fell below castrate levels by day 21 after ad ministration. D ecreases in serum prostate-specific antigen level after 3 months of therapy were also similar in both groups: 94% with the 10.8-m g depot and 9 2 .5 % with the 3.6-mg depot. For all patients, the median time to progression was 1 5 2 .7 weeks and the median time to death was 213.6 weeks. The safety profile of the 10.8-m g goserelin acetate depot was similar to that of the 3.6-mg depot; hot flashes was the most common adverse event. The incidence of injection site reactions was very low (2 [0.3% ] of 614 administra tions). Conclusions. The new 10.8-m g depot was pharmacodynamically equivalent to the current 3.6-mg depot and was well tolerated, both locally and system ically. The observed times to progression and survival were as expected in this patient population. The 10.8-mg gosereiin-acetate depot provided a dosing schedule that was convenient for the patient and the physician, and it has the potential to reduce health care costs while maintaining the quality of life in patients being treated for advanced prostate cancer.
894 ALL RIGHTS RESERVED blockade.2,3 Because the commercially available depot form ulations of LHRH analogues for pros tate cancer require adm inistration every 4 weeks, developm ent of a convenient, longer-acting depot form ulation has long been desired.
A new longer-acting, 3-m ontli depot form ula tion of the LHRH analogue goserelin acetate im plant (Zoladex, Zeneca Pharmaceuticals, W il m ington, Del, and Macclesfield, Cheshire, U.K.) was recently evaluated in clinical trials conducted in patients w ith advanced prostate cancer. In a Phase II study, effective suppression of serum con centrations of testosterone was achieved and m ain tained for at least 12 weeks following adm inistra tion of the 10.8-mg depot form ulation.4 In two Phase III studies,5,6 the pharm acodynam ics, effi cacy, and tolerabiiity of the new 10.8-mg form u lation were com pared w ith the standard 3.6-mg formulation. Effective suppression of serum tes tosterone below the castrate level w ithin 3 weeks and m aintenance of suppression for the duration of therapy was achieved w ith both the 10.8-and 3.6-mg depot formulations. The 10.8-mg depot was well tolerated both locally and systemically.5, 6 In this report, we update the pharm acodynam ic and safety results of these two Phase III studies and present an analysis of prostate-specific antigen (PSA) response, time to progression, and survival.
MATERIAL AND METHODS

Pa t i e n t S e l e c t i o n
Patients with histologic confirmation of prostate cancer, ei ther locally advanced (T3, T4) or metastatic (M l) disease, with pretreatment serum testosterone within the normal range and a life expectancy of more than 6 months were eli gible for entry. Patients previously treated with orchiectomy or hormonal treatment were excluded. All patients provided written informed consent, and the study was approved by the appropriate Institutional Review Boards.
S t u d y D e s ig n
The two multicenter, comparative studies (0001 and 1805) were of an identical, open, parallel-group design with a 48-week study period. Patients were randomized to one of two treatment groups: one group received the 10.8-mg depot for mulation at 84-day intervals throughout the study; the other group initially received a subcutaneous injection of the 3 .6-mg depot formulation of goserelin acetate, and, after three administrations at 28-clay intervals, received subcutaneous in jections of the 10.8-mg depot formulation at 84-day intervals throughout the remainder of the study.
T e s t o s t e r o n e A s s e s s m e n t s
The primary objective of these studies was to compare the pharmacodynamics of the 10.8-and 3 .6-mg goserelin acetate depots. The mean testosterone levels achieved during weeks 4 to 12 and at the end of weeks 4, 8 , and 12 were compared between the 10.8-and the 3.6-mg treatment groups. In ad dition, the serum testosterone levels of individual patients were assessed according to secondary criteria for induction (defined as testosterone levels falling below Lhe castrate level after the first administration) and maintenance (defined as serum testosterone levels remaining below the castrate level throughout a 12-week administration period).
Serum testosterone analyses were performed in a central laboratory, the Urological Research Laboratory (U R L), at the University of Nijmegen, Nijmegen, The Netherlands. Total serum testosterone was assessed using a Diagnostic Products Corporation (DPC) radioimmunoassay kit (Los Angeles, Calif). This kit was previously tested against three other methods of testosterone measurement ison was made using samples obtained from 15 patients at the Nijmegen University Hospital who were being treated with LHRH analogues; these patients w'ere not enrolled in the two studies that compared the 10.8-and 3.6-mg goserelin acetate depots.
In the current studies that compared the two depots, serum testosterone levels were measured before treatment, weekly for the first 4 weeks, then every 2 weeks until week 24, and then at weeks 36 and 48 (the day of administration of the first depot was defined as day 1). On days when sampling coincided with depot administration, samples were taken be fore administration of the depot. Serum testosterone was re corded as the mean value from duplicate assessments of the testosterone level of the sample. Internal quality-control sam ples (NMS and Lyphocheck) were included each time sam ples were assessed. When recorded results on any study day were greater than 2 nmol/L, the assessment was repeated and the new result was recorded as the testosterone value for that day, regardless of whether the new result was higher or lower than the original result. This castrate level was defined by using testosterone values in the castration range from 10 pa tients in a previous study with the goserelin acetate 10.8 -mg depot. The mean testosterone value (0.95 nm ol/L) obtained from these patients plus two standard deviations (two times 0,55 nm ol/L) was used to arrive at the castrate level of 2.0 nmol/L.
E f f i c a c y E v a l u a t i o n s
Data for PSA, time to progression, and survival were col lected retrospectively by the Trialbureau Urology in Nijmegen and verified against hospital records. PSA results were com pared between the 3.6-and 10.8-mg depots but only up until 3 months of therapy, because all patients received the 10.8-mg depot after that point. Results for time to progression and survival were combined for the two treatment groups to give an overview of disease outcome for these patients.
Changes in serum PSA alone were not considered evidence of disease progression. However, increases in PSA levels with subjective evidence of progression was considered evidence of progression.
Any one of the following was considered progression:
1. An increase greater than 50% in the value obtained when the largest diameter in one or more measurable lesions is mul tiplied by its longest perpendicular diameter 2. New soft-tissue metastasis 3. New osteolytic lesions or an increase of 25% or more in the size of existing osteolytic metastases 4. New "hot spots" on bone scintigraphy For changes in PSA levels, stabilization was defined as an increase of greater than or equal to 50% of the baseline level confirmed by two assessments not less than 2 weeks apart. A PSA increase was defined as an increase greater than 4 ng/mL in patients who previously had a complete response, or an increase greater than 50% of the baseline level in patients who previously had a partial response, each confirmed by two as sessments 2 weeks apart.
Any of the following was considered evidence of subjective progression:
1. Cancer-related decrease of greater than 25% of the he moglobin measurement or the need for more than two blood transfusions a month 2. A cancer-related weight loss greater than 15% 3. A cancer-related increase in the performance-pain-analgesic-performance score
Sa f e t y E v a l u a t io n s
All patients who received study treatment were included in the safety evaluation. Adverse events were recorded at each visit until patients completed their randomized therapy. Pa tients were solicited indirectly for adverse events; prompted by a question, each patient described anything that had both ered him since his last visit. In addition, any event considered by an investigator to be an adverse event was recorded.
S t a t i s t i c a l A n a l y s i s
Mean testosterone level was the primary end point and was analyzed statistically between weeks 4 and 12 and at the end of weeks 4, 8 , and 12. Analysis of variance (ANOVA) was used to compare mean testosterone levels between the 10.8-mg depot and the 3 .6 -mg depot for each of the two studies separately; the results were then pooled. One hundred fiftysix patients were analyzed using the intent-to-treat approach. Possible sources of variation of study, center within study, treatment, study by treatment interaction, and center by treat ment interaction were taken into account.
Successful induction required at least one sample value be ing below the castrate level after the first depot. For successful maintenance, all patients receiving at least one depot were required Lo have no sample levels above the castrate level within 84 days of a depot administration, excluding the in duction period for the first deppt. A 95% confidence interval was derived for the difference in the percentage maintenance rates between the two treatment groups to assess the precision of this comparison.
The percent fall in PSA from the baseline value after 3 months of study treatment was calculated. The number and percentage of patients whose PSA values were elevated (greater than 4 ng/mL) at baseline and fell to within the nor mal range at month 3 were tabulated and compared between the two treatment groups.
Time to progression and lime to death were estimated using the methods of Kaplan and Meier. Time to progression was defined as the number of days from the administration of the first goserelin acetate depot to the date of documentation of progression or death without progression. The time to death was defined as the number of days from the time of admin istration of the first goserelin acetate depot to the date of death from any cause. Data from patients who neither progressed nor died were censored at the time of their last visit to the clinic.
RESULTS
D e m o g r a p h y a n d Pa t i e n t C h a r a c t e r i s t i c s
The age an d body w eight of patients from both treatm ent groups in b o th studies w ere similar at entry (T able I ) . O f the 80 patients entered into each stu d y -betw een M arch 10, 1990, and July 8, 1992-67 (8 4 % ) patients in study 0001 and 66 (8 3 % ) patients in study 1805 w ere over 65 years of age.
T e s t o s t e r o n e A s s e s s m e n t s
M ean testosterone levels betw een weeks 4 and 12 and at the en d of w eeks 4, 8, and 12 were below the castrate level; there w ere no significant differ ences betw een the 10.8-an d 3.6-m g treatm ent groups (T able I I ) . Figure 1 illustrates the m ean seru m testosterone profile achieved in the two treatm ent groups. The profiles w ere sim ilar for b o th groups, w ith testos terone levels falling below the castrate level by day 21 and then rem aining below the castrate level un- (n = 65) (n = 69) til week 12. Beyond w eek 12, w hen both groups were receiving the 10.8-mg depot, levels achieved in both groups were m aintained below the castrate level. Adequate suppression of testosterone was m ain tained in 99.4% of the patients. Only 1 (0.6% ) patient did not have adequate suppression during therapy; this patient received the 10.8-mg depot. In 8 other patients, a transient elevation in testos terone levels above the castrate level was followed by a return w ithin 14 days to levels w ithin the castrate range. The clinical outcom e for these pa- tients was similar to that observed for the rest of the patients in these studies. Figure 2 shows the results of the com parison of assay results from URL and ESL. URL reported higher testosterone levels for all samples, indicat ing a clear difference between the two testosterone assays.
E f f ic a c y
PSA results were available at baseline and at 12 weeks for 54 of the 83 patients in the 3.6-mg group and 54 of the 77 patients in the 10.8-mg group. The percentages of patients w ith PSA values that fell to w ithin the norm al range following 3 m onths of study treatm ent were similar between treat ments: 26 (48% ) of 54 patients treated w ith the 3.6-mg depot and 28 (52% ) of 54 patients treated w ith the 10.8-mg depot. The m edian percentage fall in serum PSA was also similar in both groups: 92.5% for those treated w ith the 3.6-mg depot and 94.0% for those treated w ith the 10.8-mg depot.
One hundred five (66% ) of the 160 patients had progressed at the time of this analysis. The m edian time to progression was 152.7 weeks. The KaplanMeier probability of progression is presented in Figure 3 .
Eighty-three (52% ) of the 160 patients had died at the time of this analysis. Fifty-three (64% ) of the 83 patients w ho had died did so as a result of prostate cancer alone, 25 (3 0 % ) died as a result of other causes, and 5 (6% ) died as a result of u n know n causes; the observed causes of death were no t unexpected in this p atien t population, and none of the deaths w ere attrib u ted to treatm ent. The m edian tim e to d eath w as 213.6 weeks. The Kaplan-Meier probability of death is presented in Figure 4 . Safety D uring the com parative phase (w eeks 0 through 1 2 ), the only adverse event rep o rted in m ore than 5% of patients was h o t flashes, w ith an incidence of 47% in the 10.8-m g group an d 48% in the 3.6-m g group. Adverse events occurring in m ore than 5% of patients d u rin g the noncom parative phase (w eeks 12 through 4 8 ) are p resen ted in Table 111 . Only 1 patient h ad an adverse event that led to withdrawal; the p atien t h ad m ild p ru ritu s from paraneoplastic derm atitis w hile h e was receiving the 10.8-mg depot p rep aratio n of goserelin. The adverse event w as considered unrelated to therapy w ith 10.8-m g goserelin. T u m o r flare was reported in 6 patients, in clu d in g 4 in the 3.6-m g treatm ent group and 2 in the 10.8-m g treatm ent group. One patient in each group h ad a spinal cord com pres sion: 1 patient h ad m edullary com pression 8 days were hem atom as and did not require specific m an agement. A local anesthetic was not required on 597 (97% ) occasions out of 614 adm inistrations of the 10.8-mg depot. 
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COMMENT
The com bined results from the two studies, w hich include data from a total of 160 patients, dem onstrate that the 10.8-mg depot form ulation of goserelin acetate is pharm acodynam ically equivalent to three consecutive adm inistrations of the 3.6-mg depot, w ith regard to induction and m aintenance of serum testosterone suppression. Adequate suppression of serum testosterone was m aintained in 99.4% of the patients. D uring treat m ent, 9 patients had at least one serum testoster one value above the castrate level of 2.0 nm ol/L , eight of w hich were transient and isolated; how ever, the clinical outcom e of these patients, as measured by time to progression and survival, was no different from that of the rest of the patients in these studies. Only 1 patient was considered to for part of the treatm ent period; the resultant fail ure rate of 0.6% (1 of 160) was considered ac ceptable. Ultimately, w ith the continued adm in istration of goserelin acetate during the follow-up after receiving the first goserelin 3.6-m g depot; anperiod, this patient's serum testosterone level was other p atient had spinal cord com pression on the adequately suppressed and the clinical course of sam e day as the first adm inistration of the 10.8-m g goserelin depot. B oth events w ere considered by the investigator to be related to disease pro- population and assay. It also suggests that choos ing a different castrate level (for example, from literature references) may lead to different conclu sions, depending on the actual assay used. The m edian time to progression (152.7 weeks) and m edian survival time (213*6 w eeks) w ith the 10.8-mg depot were longer than those previously reported w ith the 3.6-mg depot. Kaisary et a V re ported a m edian time to treatm ent failure of 26.9 weeks and a m edian survival time of 110 weeks, w hereas Vogelzang et al. 8 reported m edian times to treatm ent failure and survival of 52 and 119 weeks, respectively; both used the 3.6-mg depot. The differences betw een the previously published reports and the current studies may be due to dif ferent patient populations; whereas the previous reports mainly studied patients with metastatic prostate cancer, the current studies included pa tients w ith both locally advanced and metastatic disease.
The adverse event profile of the 10.8-mg goser elin depot was similar to that of the 3.6-mg depot.
The 10.8-mg depot w as well tolerated, and the in cidence of injection site reactions was low (0 .3 % ). T um or flare was rep o rted in 6 patients (4 in the 3.6-m g group and 2 in the 10.8-m g g ro u p ), b u t none of the patients w ithdrew because of this ad verse event. It is possible th at coadm inistration of antiandrogen therapy w ith LHRH-A therapy could have prevented or lessened the severity of tu m o r flare in these patients.
The 10.8-mg goserelin-acetate depot is an ac ceptable and effective m eth o d for suppressing se rum testosterone levels, providing a dosing sched ule that is convenient for the patient an d the physician and th at coincides w ith the routine care of patients w ith advanced prostate cancer. The 10.8-mg depot also has the potential to reduce health care costs by red u cin g the n u m b er of health care provider contacts, w hile m aintaining the quality of life of patients being treated for ad vanced prostate cancer. 
